文献速递血脂与心血管预防

依洛尤单抗与阿托伐他汀对脂蛋白代谢的析因效应

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
PubMed 文献 · Circulation · 2016-12-09

在81名健康、血脂正常、非肥胖男性中开展2×2析因试验,比较阿托伐他汀80 mg每日与依洛尤单抗420 mg每2周皮下注射8周对VLDL、IDL和LDL载脂蛋白B动力学的影响。两种干预均独立加速VLDL-apoB、IDL-apoB和LDL-apoB的分解代谢,依洛尤单抗还降低IDL-apoB和LDL-apoB的生成速率。联合治疗对LDL-apoB和LDL-胆固醇的降低幅度显著大于任一单药治疗。

要点

  • 依洛尤单抗与阿托伐他汀均独立加速VLDL-apoB、IDL-apoB和LDL-apoB的分解代谢。
  • 依洛尤单抗降低IDL-apoB和LDL-apoB生成速率,阿托伐他汀无此作用。
  • 联合治疗降低LDL-apoB和LDL-胆固醇的幅度显著大于任一单药治疗。

核心结论

  • 在健康、血脂正常受试者中,依洛尤单抗通过加速分解代谢降低致动脉粥样硬化脂蛋白浓度,尤其LDL。
  • 依洛尤单抗还通过降低IDL和LDL生成速率降低LDL颗粒浓度,机制与阿托伐他汀不同。

研究设计与样本

  • 2×2析因试验,纳入81名健康、血脂正常、非肥胖男性。
  • 干预为阿托伐他汀80 mg每日与皮下依洛尤单抗420 mg每2周,持续8周。
  • 采用D3-亮氨酸稳定同位素输注、气相色谱/质谱和多室模型研究VLDL-apoB、IDL-apoB和LDL-apoB动力学。
  • 临床试验注册号NCT02189837。

主要发现

  • 阿托伐他汀和依洛尤单抗分别独立加速VLDL-apoB分解代谢(P<0.001和P=0.032)。
  • 阿托伐他汀和依洛尤单抗分别独立加速IDL-apoB分解代谢(P=0.021和P=0.002)。
  • 阿托伐他汀和依洛尤单抗均独立加速LDL-apoB分解代谢(两者P<0.001)。
  • 依洛尤单抗降低IDL-apoB生成速率(P=0.043)和LDL-apoB生成速率(P<0.001),阿托伐他汀无此作用。
  • 联合治疗对LDL-apoB和LDL-胆固醇浓度的降低显著大于任一单药治疗(P<0.001)。

关键数值与推荐

  • 依洛尤单抗降低游离PCSK9浓度,阿托伐他汀无此作用。
  • 阿托伐他汀降低lathosterol/campesterol比值(胆固醇合成/吸收指标)和apoC-III浓度。
  • 两种干预均降低血浆apoE,但均未显著改变脂蛋白脂肪酶和胆固醇酯转移蛋白质量或胰岛素抵抗指标。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol concentrations. Evolocumab is under investigation for its effects on cardiovascular outcomes in statin-treated, high-risk patients. The mechanism of action of PCSK9 monoclonal antibodies on lipoprotein metabolism remains to be fully evaluated. Stable isotope tracer kinetics can effectively elucidate the mode of action of new lipid-regulating pharmacotherapies. METHODS: We conducted a 2-by-2 factorial trial of the effects of atorvastatin (80 mg daily) and subcutaneous evolocumab (420 mg every 2 weeks) for 8 weeks on the plasma kinetics of very-low-density lipoprotein (VLDL)-apolipoprotein B-100 (apoB), intermediate-density lipoprotein-apoB, and LDL-apoB in 81 healthy, normolipidemic, nonobese men. The kinetics of apoB in these lipoproteins was studied using a stable isotope infusion of D3-leucine, gas chromatography/mass spectrometry, and multicompartmental modeling. RESULTS: Atorvastatin and evolocumab independently accelerated the fractional catabolism of VLDL-apoB (P<0.001 and P.032, respectively), intermediate-density lipoprotein-apoB (P=0.021 and P=.002, respectively), and LDL-apoB (P<0.001, both interventions). Evolocumab but not atorvastatin decreased the production rate of intermediate-density lipoprotein-apoB (P=0.043) and LDL-apoB (P<0.001), which contributed to the reduction in the plasma pool sizes of these lipoprotein particles. The reduction in LDL-apoB and LDL-cholesterol concentrations was significantly greater with combination versus either monotherapy (P<0.001). Whereas evolocumab but not atorvastatin lowered the concentration of free PCSK9, atorvastatin lowered the lathosterol/campesterol ratio (a measure of cholesterol synthesis/absorption) and apoC-III concentration. Both interventions decreased plasma apoE, but neither significantly altered lipoprotein lipase and cholesteryl ester protein mass or measures of insulin resistance. CONCLUSIONS: In healthy, normolipidemic subjects, evolocumab decreased the concentration of atherogenic lipoproteins, particularly LDL, by accelerating their catabolism. Reductions in intermediate-density lipoprotein and LDL production also contributed to the decrease in LDL particle concentration with evolocumab by a mechanism distinct from that of atorvastatin. These kinetic findings provide a metabolic basis for understanding the potential benefits of PCSK9 monoclonal antibodies incremental to statins in on-going clinical end point trials. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02189837.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Watts GF, Chan DC, Dent R, et al. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation. 2016. PMID: 27941065. doi:10.1161/CIRCULATIONAHA.116.025080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。